Ironwood Pharmaceuticals (NASDAQ: IRWD) is a biotechnology company that develops and commercializes therapies for gastrointestinal and rare diseases. Revenue comes primarily from LINZESS (linaclotide), its commercial product and the first FDA-approved guanylate cyclase type C agonist, marketed in the U.S. for irritable bowel syndrome with constipation in adults and pediatric patients 7 years and older, chronic idiopathic constipation in adults, and functional constipation in pediatric patients ages 6 to 17. Ironwood supports commercialization through strategic partnerships with pharmaceutical companies in international markets, where linaclotide is sold as LINZESS in Mexico, Japan, and China, and as CONSTELLA in Canada and certain European countries.

Revenue model

Product revenue and partnership arrangements tied to linaclotide, sold commercially as LINZESS in the U.S. and internationally through strategic pharmaceutical partners under the LINZESS and CONSTELLA trademarks.

Products and services

LINZESS (linaclotide), a guanylate cyclase type C agonist approved in the U.S. for IBS-C in adults and pediatric patients 7 and older, CIC in adults, and FC in pediatric patients ages 6 to 17. CONSTELLA (linaclotide) marketed in Canada and certain European countries.

Customers and end markets

Adult and pediatric patients with gastrointestinal conditions including irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation. Markets include the U.S., Mexico, Japan, China, Canada, and select European countries.

Value-chain role

Drug developer and U.S. commercializer of a branded prescription GI therapy, with international commercialization conducted through strategic pharmaceutical partnerships.

Geographic exposure

Primary commercial market is the United States. International presence through partners in Mexico, Japan, China, Canada, and certain European countries.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Agios Pharmaceuticals Inc Allogene Therapeutics Inc Travere Therapeutics Inc Iovance Biotherapeutics Inc Krystal Biotech Inc Lyell Immunopharma Inc Myriad Genetics Inc Revolution Medicines Inc Recursion Pharmaceuticals Inc